Corporate Profile

Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Change

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Jun 03
2023
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Learn More >
May 24
2023
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
Learn More >
May 11
2023
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
Learn More >
May 03
2023
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
Learn More >
Apr 26
2023
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Learn More >
Apr 25
2023
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
Learn More >
Apr 20
2023
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
Learn More >
Apr 17
2023
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
Learn More >
Apr 13
2023
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
Learn More >
Mar 30
2023
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
Learn More >
View All